---
title: The Transcriptomic Study of Thai Patients With Atopic Dermatitis by Tape Strips
nct_id: NCT05598762
overall_status: UNKNOWN
phase: NA
sponsor: Queen Sirikit National Institute of Child Health
study_type: INTERVENTIONAL
primary_condition: Atopic Dermatitis
countries: Thailand
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05598762.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05598762"
ct_last_update_post_date: 2022-11-04
last_seen_at: "2026-05-12T07:00:51.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Transcriptomic Study of Thai Patients With Atopic Dermatitis by Tape Strips

**NCT ID:** [NCT05598762](https://clinicaltrials.gov/study/NCT05598762)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Queen Sirikit National Institute of Child Health
- **Collaborators:** Mahidol University, Icahn School of Medicine at Mount Sinai, Samitivej Hospital group
- **Conditions:** Atopic Dermatitis
- **Start Date:** 2022-12
- **Completion Date:** 2024-07
- **CT.gov Last Update:** 2022-11-04

## Brief Summary

This study will be use the tape strip technique to evaluate the skin biomarkers of atopic dermatitis among Thai patients to differentiate clinical phenotype.

## Detailed Description

The patients will be enrolled in this study if they have been diagnosed with atopic dermatitis. All participants (AD patients and controls) will be evaluated their skin biomarkers by using tape stripping. The tape strips will be applied to the antecubital fossa to collect the epithelial samples. Then RNA was extracted from the tape strips for mRNA profiling to identify the immune and epidermal barrier genes.

## Eligibility

- **Minimum age:** 1 Year
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Children (age 1-18 years old) with mild atopic dermatitis
* Children (age 1-18 years old) with moderate to severe atopic dermatitis
* Children (age 1-18 years old) with moderate to severe atopic dermatitis and food allergy
* Adult (age 18-60 years old) with atopic dermatitis
* Healthy individuals (1-60 years old)
* Patients with asthma (1-60 years old)

Exclusion Criteria:

* Active skin infections
* Used systemic immunosuppressants within 4 weeks
* Used topical steroids or immunomodulators within 1 week
* Used moisturizers within 12 hours before evaluation
```

## Arms

- **Children with mild atopic dermatitis** (ACTIVE_COMPARATOR) — * age 1-8 years old
* mild degree of atopic dermatitis
- **Children with moderate-severe atopic dermatitis** (ACTIVE_COMPARATOR) — * age 1-8 years old
* moderate or severe degree of atopic dermatitis
- **Children with food allergy and moderate-severe atopic dermatitis** (ACTIVE_COMPARATOR) — * age 1-8 years old
* moderate or severe degree of atopic dermatitis
* IgE mediated food allergy
- **Adult with atopic dermatitis** (ACTIVE_COMPARATOR) — * age 18-60 years old
* mild-severe atopic dermatitis
- **Healthy** (ACTIVE_COMPARATOR) — * age 1-60 years old
* no history of atopic diseases
- **Healthy with Asthma** (ACTIVE_COMPARATOR) — * age 1-8 years old
* doctor diagnosed asthma
* no history of chronic or chronic relapsing eczema

## Interventions

- **Tape strips** (GENETIC) — Tape strip is a minimally invasive method that captures the stratum corneum. It is use to identify skin biomarkers in atopic dermatitis.

## Primary Outcomes

- **Cellular AD biomarkers** _(time frame: 1 month)_ — Evaluated by RNA sequencing: RNA was extracted for real-time polymerase chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0
- **Immune biomarkers** _(time frame: 1 month)_ — Evaluated by RNA sequencing: RNA was extracted for real-time polymerase chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0
- **Barrier biomarkers** _(time frame: 1 month)_ — chain reaction (RT-PCR) with the miRNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription to complementary DNA (cDNA) from RNA was carried out using the High Capacity cDNA reverse transcription (Thermo fisher). TaqMan Low Density Array (TLDA) cards (Thermo fisher) were used for quantitative reverse transcription polymerase chain reaction (qRT-PCR). 500pg total RNA was used for PreAMP pool. Eukaryotic 18S recombinant RNA (rRNA) was used as an endogenous control. Expression values were normalized to Rplp0

## Locations (1)

- Queen Sirikit National Institute of Child Health, Bangkok, Thailand

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.queen sirikit national institute of child health|bangkok||thailand` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05598762.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05598762*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*